Latest news with #ConferenceCall
Yahoo
2 days ago
- Business
- Yahoo
SWK Holdings Corporation Announces Financial Results for Second Quarter 2025
Conference Call Scheduled for Friday, August 15, 2025, at 09:00 a.m. CST Corporate Highlights Second quarter 2025 GAAP net income was $3.5 million, compared with GAAP net income of $3.7 million for the second quarter 2024. Second quarter 2025 finance receivables segment adjusted non-GAAP net income was $4.6 million, compared with adjusted non-GAAP net income of $2.6 million for the second quarter 2024. As of June 30, 2025, net finance receivables were $237.6 million, a 10.4% decrease from June 30, 2024 driven primarily by the monetization of the majority of SWK's royalty portfolio. The second quarter 2025 effective yield was 14.1%, a 50 basis point decrease from second quarter 2024. As of June 30, 2025, GAAP book value per share was $20.23, an 11.0% decrease from $22.72 on June 30, 2024. When adjusted to exclude the $4.00 per share dividend paid during the quarter, this figure would have been $24.46, a 6.8% increase year-over-year. As of June 30, 2025, non-GAAP tangible financing book value per share was $18.47, an 8.3% decrease from $20.14 as of June 30, 2024. When adjusted to exclude the $4.00 per share dividend paid during the quarter, this figure would have been $22.50, an 11.7% increase year-over-year. DALLAS, TX / / August 14, 2025 / SWK Holdings Corporation (NASDAQ:SWKH) ("SWK" or the "Company"), a life science-focused specialty finance company catering to small- and mid-sized commercial-stage companies, today provided a business update and announced its financial and operating results for the second quarter ended June 30, 2025. SWK CEO Jody Staggs said "During the second quarter, we sold the majority of our royalty portfolio for approximately book value and paid a $4.00 per share dividend to our shareholders. After the quarter closed, we sold the majority of the assets at our MOD3 subsidiary to a strategic partner at a slight premium to book value. These actions have simplified the business and allow the team to focus on our core life science loan strategy." "During the second quarter we generated $3.5 million of GAAP net income and $4.6 million of finance receivables segment adjusted non-GAAP net income. Following the royalty monetization and sale of the MOD3 assets, our non-cash assets include approximately $234.1 million of performing, gross finance receivables with a 14.1% effective yield, $12.3 million of non-performing gross finance receivables, and $5.2 million of public equities and warrants. Against this value SWK carries an $8.8 million allowance for credit losses. SWK also owns equity and warrants in private companies as well as earn-outs that are carried at zero for GAAP accounting purposes, although SWK believes these assets have economic value." "Our GAAP book value per share totaled $20.23, a 6.8% increase year-over-year when excluding the $4.00 per share dividend paid during the quarter. Our non-GAAP tangible financing book value totaled $18.47, an 11.7% year-over-year increase after considering the $4.00 per share special dividend paid during the second quarter. Given the monetization of the MOD3 assets, this figure is now calculated by taking total book value and removing the remaining MOD3 intangible assets as well as the deferred tax asset." Mr. Staggs concluded, "We continue to pursue financings to innovative life science companies with a focus on supporting our existing, performing borrowers. During the quarter we advanced $13.5 million to two performing borrowers, and after quarter close, ImpediMed achieved a performance milestone triggering the draw of a $5.0 million Tranche B commitment. We believe our portfolio of cash-yielding, life science receivables is an attractive asset and view the sale of the majority of our royalty portfolio and MOD3 assets at approximately book value as supportive of this view." Second Quarter 2025 Financial Results For the second quarter 2025, SWK reported total revenue of $10.1 million, a 6.5% decrease compared to $10.8 million for the second quarter 2024. The $0.7 million decrease in revenue for the three months ended June 30, 2025 consisted of a $1.2 million decrease in Finance Receivables segment revenue, driven by the sale of the majority of our royalty portfolio, offset by a $0.5 million increase in Pharmaceutical Development segment revenue. Income before income tax expense for the quarter was $4.6 million and $4.7 million for the three months ended June 30, 2025 and 2024, respectively. Second quarter 2025 income before income tax expense benefited from a decrease in provision expense, offset by a decrease in gains on warrant exercises and a revaluation of finance receivables, relative to the same period in the prior year. GAAP net income for the quarter ended June 30, 2025, decreased to $3.5 million, or $0.29 per diluted share, from $3.7 million, or $0.30 per diluted share, for the second quarter 2024. For the second quarter 2025, non-GAAP adjusted net income was $4.6 million, or $0.38 per share. Non-GAAP adjusted net income for the Finance Receivables segment was $4.6 million, an increase from $2.6 million for the second quarter 2024. Total investment assets (defined as finance receivables, net of allowance for credit losses, marketable investments, and warrant assets) were $242.8 million as of June 30, 2025, an 8.9% decrease compared with total investment assets of $266.7 million as of June 30, 2024. The decline was primarily due to the monetization of the majority of the company's royalty assets during the first and second quarters for total proceeds of approximately $51.3 million. The allowance for credit losses at quarter's end totaled $8.8 million, a decrease of $4.3 million from the second quarter of 2024. During the second quarter SWK repurchased 58,954 shares for a total purchase price of $0.9 million. Year-to-date through August 8, 2025,SWK repurchased 198,162 shares for a total purchase price of $3.0 million. GAAP book value per share was $20.23 as of June 30, 2025, an 11.0%decrease compared to $22.72 as of June 30, 2024 and a 6.8% increase after considering the $4.00 per share special dividend. Non-GAAP tangible financing book value per share totaled $18.47, an 8.3%decrease compared to $20.14 at June 30, 2024 and an 11.7% increase after considering the $4.00 per share special dividend. Management views non-GAAP tangible financing book value per share as a relevant metric to value the Company's core finance receivable business. Non-GAAP tangible financing book value per share removes the value of the deferred tax assets and MOD3 net asset value. Portfolio Status During the second quarter, SWK sold the majority of the royalty portfolio for $34.0 million and paid a $49.1 million dividend to shareholders. During the second quarter, we funded an additional $11.0 million to performing borrower AOTI, Inc as well as $2.5 million to performing borrower Nicoya Life Sciences, Inc. After the quarter close ImpediMed Limited ("ImpediMed") achieved a performance milestone, which triggered the draw of the $5.0 million Tranche B. The second quarter 2025 effective yield was 14.1%, a 50 basis points decrease from 14.6% in the second quarter 2024. The effective yield is the rate at which income is expected to be recognized if payments are received pursuant to the terms of the finance receivables. The second quarter 2025 realized yield of the finance receivable portfolio was 14.3%, a 110 basis point decrease from 15.4% in second quarter 2024. The realized yield is inclusive of all fees, including all realized unamortized fees, amendment fees, and prepayment fees, and is calculated based on the simple average of finance receivables at the beginning and end of the period. The realized yield may differ from the effective yield due to actual cash collections being greater or lesser than modeled. As of June 30, 2025, the Company had three finance receivables in nonaccrual status: (1) the Flowonix Medical, Inc. ("Flowonix") royalty, with a carrying value of $7.1 million; (2) the Best ABT, Inc. ("Best") royalty, with a carrying value of $2.3 million; and (3) the Ideal Implant, Inc. ("Ideal") royalty, with a carrying value of $2.8 million. SWK impaired the carrying value of Flowonix and Ideal royalties by $0.3 million and $0.2 million, respectively, during the quarter. After second quarter close, SWK received a $0.5 million payment from the Flowonix estate, which will be applied against the carrying value. As of June 30, 2025, the Company had $7.5 million of unfunded commitments and $2.5 million after accounting for funding the $5.0 million Tranche B commitment to ImpediMed in July. Total portfolio investment activity was as follows (in thousands): Three Months Ended June 30, 2025 2024 Beginning Portfolio $ 227,776 $ 261,895 Investment in finance receivables 13,500 7,000 Paydowns received on investments (466 ) (1,641 ) Paydowns received on royalties - (847 ) Interest paid in kind 640 426 Loan discount and fee accretion 1,388 1,410 Warrant and equity investments, net of sales and cancellations 83 360 Net unrealized gain on marketable investments and warrant assets 384 212 Foreign currency gains (losses) on finance receivables 55 (432 ) Provision for credit losses (541 ) (4,215 ) Gain on revaluation of finance receivables - 2,495 Ending Portfolio $ 242,819 $ 266,663 Adjusted Non-GAAP Net Income The following table provides a reconciliation of SWK's reported (GAAP) consolidated net income to SWK's adjusted consolidated net income (Non-GAAP): Three Months Ended June 30, 2025 2024 Net income $ 3,536 $ 3,680 Income tax expense 1,026 1,035 MOD3 amortization expense - 196 Unrealized net gain on warrant assets (347 ) (226 ) Gain on exercise of warrant - (675 ) Unrealized net (gain) loss on marketable investments (37 ) 19 Foreign currency transaction (gains) losses 451 (437 ) Gain on revaluation of finance receivables - (2,495 ) Intangible asset impairment expense - 5,771 Change in fair value of acquisition-related contingent consideration - (4,900 ) Adjusted income before income tax expense 4,629 1,968 Adjusted income tax expense - - Non-GAAP net income $ 4,629 $ 1,968 In the table above, management has deducted the impact of the following items: (i) change in the fair-market value of equities and warrants, (ii) income taxes, as the Company has substantial net operating losses to offset against future income, (iii) amortization expense associated with MOD3 intangible assets, (iv) gain on revaluation of finance receivable held for sale, (v) change in fair value of acquisition-related contingent consideration, (vi) intangible asset impairment, and (vii) foreign currency (gains) losses. Finance Receivables Adjusted Non-GAAP Net Income The following table provides a reconciliation of SWK's consolidated adjusted non-GAAP net income before provision for income tax expense, listed in the table above, to the finance receivables non-GAAP adjusted net income. The table eliminates MOD3 operating loss. The adjusted net income before income tax expense is derived in the table above and eliminates MOD3 operating income (loss), excluding MOD3 amortization expenses. Three Months Ended June 30, 2025 2024 Non-GAAP net income $ 4,629 $ 1,968 MOD3 operating (income) loss, excluding amortization expense (18 ) 670 Adjusted Finance Receivable segment income before income tax expense $ 4,611 $ 2,638 Adjusted income tax expense - - Finance Receivables segment adjusted non-GAAP net income $ 4,611 $ 2,638 Non-GAAP Tangible Finance Book Value Per Share The following table provides a reconciliation of SWK's GAAP book value per share to its non-GAAP tangible finance book value per share. The table eliminates the deferred tax assets, intangible assets, MOD3 property and equipment and acquisition-related contingent consideration (in thousands, except per share data): Three Months Ended June 30, 2025 2024 GAAP stockholder's equity $ 246,469 $ 282,831 Outstanding shares (1) 12,184 12,447 GAAP book value per share $ 20.23 $ 22.72 Less: Deferred tax assets, net (21,219 ) (27,052 ) Less: Intangible assets, net (209 ) (232 ) Less: Goodwill - - Less: MOD3 property and equipment, net - (4,921 ) Non-GAAP tangible finance book value 225,041 250,626 Outstanding shares (1) 12,184 12,447 Non-GAAP Tangible book value per share $ 18.47 $ 20.14 (1) Outstanding shares computed as of quarter end. Non-GAAP Financial Measures This release includes non-GAAP adjusted net income, non-GAAP finance receivable segment net income, and non-GAAP tangible financing book value per share, which are metrics that are not compliant with generally accepted accounting principles in the United States (GAAP). Non-GAAP adjusted net income is adjusted for certain items including (i) changes in the fair-market value of public equity-related assets and SWK's warrant assets as mark-to-market changes are non-cash, (ii) income taxes as the Company has substantial net operating losses to offset against future income, (iii) changes in the fair-market value of contingent consideration associated with the MOD3 acquisition, and (iv) depreciation and amortization expenses, primarily associated with the 2019 acquisition of MOD3. In addition to the adjustments noted above, non-GAAP finance receivable segment net income also excludes MOD3 operating gains or losses. Non-GAAP tangible financing book value per share excludes the deferred tax asset, intangible assets, and contingent consideration associated with the MOD3 transaction. These non-GAAP measures may not be directly comparable to similar measures used by other companies in the Company's industry, as other companies may define such measures differently. Management believes that these measures are useful to investors and management in understanding our ongoing operations and in analysis of ongoing operating trends and provides useful additional information relating to our operations and financial condition. The Company encourages investors to carefully consider its results under GAAP, as well as its supplemental non-GAAP information and the reconciliation between these presentations, to better understand its business. Non-GAAP financial results are reported in addition to, and not as a substitute for, or superior to, financial measures calculated in accordance with GAAP. Further, non-GAAP financial measures, even if similarly titled, may not be calculated in the same manner by all companies, and therefore should not be compared. Conference Call Information SWK Holdings will host a conference call on August 15, 2025, at 9:00 a.m. CST, to discuss its corporate and financial results for the second quarter 2025. Interested participants and investors may access the call via the numbers below: 888-506-0062 (U.S.) 973-528-0011 (International) The participant Access Code is 117203 or ask for the SWK Holdings call. An archive of the webcast will remain available on the SWK Holdings' website for 12 months, starting later that day. About SWK Holdings Corporation SWK Holdings Corporation is a life science focused specialty finance company partnering with small- and mid-sized commercial-stage healthcare companies. SWK provides non-dilutive financing to fuel the development and commercialization of lifesaving and life-enhancing medical technologies and products. SWK's unique financing structures provide flexible financing solutions at an attractive cost of capital to create long-term value for all SWK stakeholders. SWK's solutions include structured debt, traditional royalty monetization, synthetic royalty transactions, and asset purchases typically ranging in size from $5.0 million to $25.0 million. Additional information on the life science finance market is available on the Company's website at Safe Harbor for Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements including words such as "believes," "expects," "anticipates," "intends," "estimates," "plan," "will," "may," "look forward," "intend," "guidance," "future" or similar expressions are forward-looking statements. Because these statements reflect SWK's current views, expectations and beliefs concerning future events, these forward-looking statements involve risks and uncertainties. Investors should note that many factors, as more fully described under the caption "Risk Factors" and elsewhere in SWK's Form 10-K, Form 10-Q and Form 8-K filings with the Securities and Exchange Commission and as otherwise enumerated herein, could affect the Company's future financial results and could cause actual results to differ materially from those expressed in such forward-looking statements. The forward-looking statements in this press release are qualified by these risk factors. These are factors that, individually or in the aggregate, could cause the Company's actual results to differ materially from expected and historical results. You should not place undue reliance on any forward-looking statements, which speak only as of the date they are made. We assume no obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise. For more information, please contact: Investor Relations and MediaSusan Xu728-323-0959investorrelations@ SWK HOLDINGS CORPORATIONUNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS(in thousands, except share data) June 30, 2025 December 31, 2024 Assets Current assets: Cash and cash equivalents $ 8,006 $ 5,927 Interest, accounts receivable, and other receivables, net 5,611 5,788 Assets held for sale, net 6,488 6,398 Other current assets 1,088 2,141 Total current assets 21,193 20,254 Finance receivables, net of allowance for credit losses of $8,826 and $11,249 as of June 30, 2025 and December 31, 2024, respectively 237,604 277,760 Collateral on foreign currency forward contract - 2,750 Marketable investments 603 580 Deferred tax assets, net 21,219 23,484 Warrant assets 4,612 4,366 Other non-current assets 466 3,041 Total assets $ 285,697 $ 332,235 Liabilities and Stockholders' Equity Current liabilities: Accounts payable and accrued liabilities $ 2,101 $ 2,810 Liabilities held for sale 1,278 1,255 Deferred income 3,300 1,500 Total current liabilities 6,679 - 5,565 Unsecured senior notes, net 31,736 31,412 Revolving credit facility 294 6,233 Other non-current liabilities 519 335 Total liabilities 39,228 43,545 Stockholders' equity: Preferred stock, $0.001 par value; 5,000,000 shares authorized; no shares issued and outstanding - - Common stock, $0.001 par value; 250,000,000 shares authorized; 12,183,906 and 12,213,599 shares issued and outstanding as of June 30, 2025 and December 31, 2024, respectively 12 12 Additional paid-in capital 4,418,773 4,419,991 Accumulated deficit (4,172,316 ) (4,131,313 ) Total stockholders' equity 246,469 288,690 Total liabilities and stockholders' equity $ 285,697 $ 332,235 SWK HOLDINGS CORPORATIONUNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF INCOME(in thousands, except per share data) Three Months Ended June 30, Six Months Ended June 30, 2025 2024 2025 2024 Revenues: Finance receivable interest income, including fees $ 8,543 $ 9,986 $ 19,255 $ 21,021 Pharmaceutical development 1,190 804 2,153 1,083 Other 319 57 476 103 Total revenues 10,052 10,847 21,884 22,207 Costs and expenses: Provision (benefit) for credit losses 761 4,095 (704 ) 9,392 Loss on impairment of intangibles assets - 5,771 - 5,771 Interest expense 1,155 1,119 2,285 2,375 Pharmaceutical manufacturing, research and development expense 645 520 1,403 1,050 Change in fair value of acquisition-related contingent consideration - (4,900 ) - (4,900 ) Depreciation and amortization expense 19 421 38 935 General and administrative expense 2,843 2,920 6,120 5,604 Income from operations 4,629 901 12,742 1,980 Other income (expense), net Unrealized net loss on warrants 347 226 (77 ) 131 Net loss on exercise and cancellation of warrants - 675 - 444 Net loss on marketable investments 37 (19 ) (68 ) (162 ) Loss on sale of assets - - (82 ) - Realized gain on early payment of finance receivable - - 1,729 - Gain (loss) on revaluation of finance receivables - 2,495 (3,727 ) 2,495 Realized and unrealized foreign currency transaction gains (451 ) 437 (138 ) 524 Income before income tax expense 4,562 4,715 10,379 5,412 Income tax expense 1,026 1,035 2,304 1,264 Net income $ 3,536 $ 3,680 $ 8,075 $ 4,148 Net income per share Basic $ 0.29 $ 0.30 $ 0.66 $ 0.33 Diluted $ 0.29 $ 0.30 $ 0.66 $ 0.33 Weighted average shares outstanding Basic 12,208 12,458 12,218 12,467 Diluted 12,208 12,470 12,218 12,484 SWK HOLDINGS CORPORATIONUNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS(in thousands) Six Months Ended June 30, 2025 2024 Cash flows from operating activities: Net income $ 8,075 $ 4,148 Adjustments to reconcile net income to net cash provided by operating activities: Provision (benefit) for credit losses (704 ) 9,392 Debt issuance costs (41 ) - Loss on impairment of intangible assets - 5,771 Right-of-use amortization and cease use costs 112 261 Amortization of debt issuance costs 548 491 Deferred income taxes, net 2,266 1,239 Unrealized net (gain) loss on warrants 77 (131 ) Net gain on exercise and cancellation of warrants - (444 ) Loss from sale of assets 82 - Change in fair value of acquisition-related contingent consideration - (4,900 ) (Gain) loss on revaluation of finance receivable 3,727 (2,495 ) Foreign currency transaction (gain) loss (614 ) (1,587 ) Loss on marketable investments 68 162 Loan discount amortization and fee accretion (2,956 ) (2,214 ) Interest paid-in-kind (826 ) (904 ) Stock-based compensation 608 360 Depreciation and amortization expense 38 935 Changes in operating assets and liabilities: Interest, accounts receivable and other receivables, net 177 (2,655 ) Foreign currency forward contract 915 1,260 Collateral returned for derivative instruments 2,750 - Other assets 850 (150 ) Accounts payable, accrued expenses, and other non-current liabilities (871 ) (903 ) Deferred income 1,800 2,207 Net cash provided by operating activities 16,081 9,843 Cash flows from investing activities: Proceeds from sale of property and equipment 110 - Settlement of foreign currency forward contract 1,560 - Sale of marketable investments - 574 Investment in finance receivables (23,500 ) (7,446 ) Proceeds from sale of investments 31,678 - Repayment of finance receivables 33,141 11,693 Corporate debt securities principal payments 15 13 Purchases of property and equipment (163 ) (21 ) Net cash provided by investing activities 42,841 4,813 Cash flows from financing activities: Net settlement for employee taxes on stock options (89 ) (43 ) Net payments on credit facility (5,939 ) (12,350 ) Cash dividends (49,078 ) - Repurchases of common stock, including fees and expenses (1,737 ) (1,950 ) Net cash used in financing activities (56,843 ) (14,343 ) Net increase in cash, cash equivalents, and restricted cash 2,079 313 Cash, cash equivalents, and restricted cash at beginning of period 5,927 5,236 Cash, cash equivalents, and restricted cash at end of period $ 8,006 $ 5,549 Supplemental non-cash investing and financing activities: Cash paid for interest $ 1,517 $ 875 SOURCE: SWK Holdings Corp View the original press release on ACCESS Newswire
Business Wire
2 days ago
- Business
- Business Wire
Nu Holdings Ltd. Reports Second Quarter 2025 Financial Results
SíO PAULO--(BUSINESS WIRE)--Nu Holdings Ltd. (NYSE: NU) ('Nu' or the 'Company'), one of the largest digital financial services platforms in the world, released its Second Quarter 2025 financial results today. Financial results are expressed in U.S. dollars and are presented in accordance with International Financial Reporting Standards (IFRS). The full earnings release has been made available on the Company's Investor Relations website at as well as the details of the Earnings Conference Call Nu will hold today at 6:00 pm Eastern time/7:00 pm Brasilia time. "In Q2'25, we achieved another quarter of robust growth, expanding our customer base to nearly 123 million with over 4.1 million net additions, and maintaining an activity rate above 83%. This strong engagement drove revenues to $3.7 billion, representing an 85% annualized growth rate since 2021, and allowed us to nearly triple our quarterly net income to $637 million in the past two years. These results come despite our ongoing investments in growth and, most importantly, in keeping our customers loving us fanatically, proving that it's possible to scale efficiently, with discipline, and still generate strong earnings while building the foundation for the long-term', says David Vélez, founder and CEO of Nubank. Q2'25 Results Snapshot Below are the Q2'25 performance highlights of Nu Holdings Ltd.: Operating Highlights: Customer growth: Nu added 4.1 million new customers in Q2'25, a 17% year-over-year (YoY) increase, reaching a total of 122.7 million customers globally. This expansion reinforces Nu's position as one of the world's largest and fastest-growing digital financial services platforms. In Brazil, Nu is the third-largest financial institution by number of customers, according to the Brazilian Central Bank. Engagement and activity rates: Monthly Average Revenue per Active Customer (ARPAC) crossed the $12 mark for the first time, reaching $12.2 in Q2'25, up 18% YoY on a FX-neutral basis 1 (FXN), and $27.3 for customers with over eight years on the platform. The monthly activity rate 2 is 83.2%. Low-cost operating platform: Monthly Average Cost to Serve Per Active Customer remained stable at $0.80 per customer. Asset Quality 3: Nu's leading indicator of asset quality, the 15 to 90-day NPL ratio, declined 30 basis points (bps) QoQ to 4.4% in Q2'25. The 90+ NPL ratio increased by 10 bps to 6.6%, reflecting the rise in early delinquency observed in Q1'25 and following the usual seasonal pattern. Financial Highlights: Net & Adjusted Income: Net Income increased by 42% YoY FXN to $637 million, compared to $487.3 million in Q2'24, and the annualized ROE was 28% - well above industry peers. Adjusted Net Income 4 increased to $694.5 million. Revenue: Nu's Q2'25 revenues increased 40% YoY FXN, reaching a record of $3.7 billion. Gross Profit: Nu's gross profit totaled $1.55 billion in Q2'25, up 14% FXN sequentially and 24% YoY on FXN, reflecting NII expansion and stable credit allowances. Gross profit margin also improved by 160 bps QoQ to 42.2%. Liquidity: Deposits increased 41% YoY FXN to $36.6 billion, while the cost of funding reached 91% of the blended interbank rates for the quarter. Total receivables across Nu's credit card and loan portfolios expanded 40% YoY FXN and 8% QoQ FXN to $27.3 billion, while its total Interest-Earning Portfolio (IEP) increased 55% YoY FXN to $15.7 billion as of June 30, 2025. Net Interest Income: Increased 33% YoY and 11% QoQ on FXN, reaching a new all-time high of $2.1 billion. The net interest margin (NIM) rose 20 bps to 17.7%. Nu Holdings' risk-adjusted NIM expanded by 100 bps, reaching 9.2% in Q2'25. Business highlights Performance and Growth in Brazil: In Brazil, our customer base reached 107.3 million as of June 30, 2025, which represents over 60% of Brazil's adult population, and 60% of those customers use Nu as their primary financial relationship. The deposit base has grown to $27.8 billion, reflecting the strength of our brand and customer trust. International expansion: In Mexico, our customer base reached 12 million customers, now serving around 13% of Mexico's adult population. Deposits reached $6.7 billion. In Colombia, our customer base reached 3.4 million customers, serving nearly 10% of Colombia's adult population and deposits increased 841% FXN YoY to $2.1 billion in Q2'25. Multi-growth platform: In Q2'25, the active credit customer base reached 55 million (+11 YoY). The total credit card base increased to 6.6 million (+52% YoY) in Mexico, and to 1.4 million (+34% YoY) in Colombia. Nu expanded its customer base segments in SME to 5.2 million (+23% YoY), Super Core to 9.8 million (+ 14% YoY), High Income to 3 million (+ 13% YoY) and Mass Market to 104.7 million (+18% YoY). The active unsecured loans customers reached 13.6 million (+56% YoY), and active secured loans customers reached 6.8 million (+158% YoY). Active investments and crypto customers base reached 36.2 million (+70% YoY) and 6.6 million (+41% YoY), respectively. Those elements together have broadened our platform into a powerful multi-product, multi-segment, and multi-geo growth engine. Footnotes 1 FX neutral measures were calculated to present what such measures in preceding periods/years would have been had exchange rates remained stable from these preceding periods/years until the date of the Company's more recent financial information. 2 Activity rate is defined as monthly active customers divided by the total number of customers as of a specific date. 3 Brazil Only 4 Adjusted Net Income is a non-IFRS measure calculated using Net Income adjusted for expenses related to Nu's share-based compensation as well as the hedge accounting and tax effects related to these items, among others. For more information, please see 'Non-IFRS Financial Measures and Reconciliations – Adjusted Net Income Reconciliation". Note on forward-looking statements and non-IFRS financial measures This release speaks at the date hereof and the Company is under no obligation to update or keep current the information contained in this presentation. Any information expressed herein is subject to change without notice. Any market or other third-party data included in this presentation has been obtained by the Company from third-party sources. While the Company has compiled and extracted the market data, it can provide no assurances of the accuracy and completeness of such information and takes no responsibility for such data. This release contains forward-looking statements. All statements other than statements of historical fact contained in this presentation may be forward-looking statements and include, but are not limited to, statements regarding the Company's intent, belief or current expectations. These forward-looking statements are subject to risks and uncertainties, and may include, among others, financial forecasts and estimates based on assumptions or statements regarding plans, objectives and expectations. Although the Company believes that these estimates and forward-looking statements are based upon reasonable assumptions, they are subject to several risks and uncertainties and are made in light of information currently available, and actual results may differ materially from those expressed or implied in the forward-looking statements due to various factors, including those risks and uncertainties included under the captions 'Risk Factors' and 'Management's Discussion and Analysis of Financial Condition and Results of Operations' in the prospectus dated December 8, 2021 filed with the Securities and Exchange Commission pursuant to Rule 424(b) under the Securities Act of 1933, as amended, and in the Annual Report on Form 20-F for the year ended December 31, 2024, which was filed with the Securities and Exchange Commission on April 16, 2025. The Company, its advisers and each of their respective directors, officers and employees disclaim any obligation to update the Company's view of such risks and uncertainties or to publicly announce the result of any revision to the forward-looking statements made herein, except where it would be required to do so under applicable law. The forward-looking statements can be identified, in certain cases, through the use of words such as 'believe,' 'may,' 'might,' 'can,' 'could,' 'is designed to,' 'will,' 'aim,' 'estimate,' 'continue,' 'anticipate,' 'intend,' 'expect,' 'forecast', 'plan', 'predict', 'potential', 'aspiration,' 'should,' 'purpose,' 'belief,' and similar, or variations of, or the negative of such words and expressions. The financial information in this document includes forecasts, projections and other predictive statements that represent the Company's assumptions and expectations in light of currently available information. These forecasts, projections and other predictive statements are based on the Company's expectations and are subject to variables and uncertainties. The Company's actual performance results may differ. Consequently, no guarantee is presented or implied as to the accuracy of specific forecasts, projections or predictive statements contained herein, and undue reliance should not be placed on the forward-looking statements in this presentation, which are inherently uncertain. In addition to IFRS financials, this presentation includes certain summarized, non-audited or non-IFRS financial information. These summarized, non-audited or non-IFRS financial measures are in addition to, and not a substitute for or superior to, measures of financial performance prepared in accordance with IFRS. References in this presentation to 'R$' refer to the Brazilian Real, the official currency of Brazil. About Nu Nu is one of the largest digital financial services platforms in the world, serving more than 122 million customers across Brazil, Mexico, and Colombia. The company has been leading an industry transformation by leveraging data and proprietary technology to develop innovative products and services. Guided by its mission to fight complexity and empower people, Nu caters to customers' complete financial journey, promoting financial access and advancement with responsible lending and transparency. The company is powered by an efficient and scalable business model that combines low cost to serve with growing returns. Nu's impact has been recognized in multiple awards, including Time 100 Most Influential Companies, Fast Company's Most Innovative Companies, and Forbes World's Best Banks. For more information, please visit
Yahoo
2 days ago
- Business
- Yahoo
Elite Pharmaceuticals, Inc. Reports Financial Results for the First Quarter of Fiscal Year 2026 ended June 30, 2025 and Provides Conference Call Information
Conference Call Scheduled for Friday, August 15 at 11:30 AM EDT Northvale, New Jersey--(Newsfile Corp. - August 14, 2025) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company developing niche generic products, announced results for the first quarter of fiscal year 2026 ended June 30, 2025 ("First Quarter"). Consolidated revenues for the three-month period ending June 30, 2025, were $40.2 million, an increase of $21.4 million or approximately 114% as compared to the comparable period of the prior fiscal year. Operating profits were $21.7 million, an increase of $17.8 million or approximately 462%, as compared to the comparable period of the prior fiscal year. The increase in operating profits was primarily attributed to sales of Elite's lisdexamfetamine products, which were launched after the comparable period of the prior fiscal year, as well as overall strong growth in the Elite label product lines as compared to the comparable period in the prior fiscal year. Conference Call Information Elite's management will host a conference call to discuss the First Quarter of Fiscal Year 2026 financial results and provide an update on recent business developments. Stockholder questions should be submitted to the company in advance of the call. Date: August 15, 2025 Time: 11:30 AM EDT Dial-in numbers: 1-800-346-7359 (domestic)1-973-528-0008 (international) Conference number: 98840 Questions: dianne@ Financial questions by 7:00 PM EDT on Thursday, August 14, 2025 Audio Replay: The financial statements can be viewed for Elite's First Quarter of Fiscal Year 2026 on Form 10-Q here. About Elite Pharmaceuticals, Pharmaceuticals, Inc. is a specialty pharmaceutical company that develops and distributes niche generic products. Elite specializes in developing, manufacturing, and distributing oral, controlled-release drug products. Elite owns multiple generic products, which it distributes nationally under the Elite Laboratories, Inc. label. Elite also has products licensed to TAGI Pharma. Elite operates a cGMP and DEA-registered research, development, and manufacturing facility in Northvale, NJ. For more information, visit This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including, without limitation, those related to the effects, if any, on future results, performance or other expectations that may have some correlation to the subject matter of this press release. Readers are cautioned that such forward-looking statements involve, without limitation, risks, uncertainties and other factors not under the control of Elite, which may cause actual results, performance or achievements of Elite to be materially different from the results, performance or other expectations that may be implied by these forward-looking statements. These forward-looking statements may include statements regarding the expected timing of approval, if at all, of products by the FDA, and the actions the FDA may require of Elite in order to obtain such approvals. These forward-looking statements are not guarantees of future action or performance. These risks and other factors are discussed, without limitation, in Elite's filings with the Securities and Exchange Commission, including its reports on forms 10-K, 10-Q, and 8-K. Elite is under no obligation to update or alter its forward-looking statements, whether as a result of new information, future events or otherwise. Contact:For Elite Pharmaceuticals, Will, Investor Relations, 518-398-6222Dianne@ To view the source version of this press release, please visit Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Yahoo
05-08-2025
- Business
- Yahoo
NeurAxis to Host Second Quarter 2025 Results and Business Update Call on Tuesday, August 12, 2025
Financial results to be released before market open; Conference call to be conducted at 9:00 a.m. Eastern Time CARMEL, Ind., Aug. 05, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. ('NeurAxis,' or the 'Company') (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing chronic and debilitating conditions in children and adults, will report financial results for its second quarter 2025, for the period ended June 30, 2025, on Tuesday, August 12, 2025, before market open. The Company has scheduled a conference call for the same day, Tuesday, August 12, 2025, at 9:00 am ET to review the results. Conference Call Details Date and Time: Tuesday, August 12, 2024, at 9:00am ET Live Webcast Information: Interested parties can access the conference call via a live webcast, which is available in the Investor Relations section of the Company's website at or For participants listening through the webcast, questions can be sent in through the portal using the 'Ask a Question' link or by emailing questions to NRXS@ Call-in Information: Interested parties can also access the live conference call by initially registering at the following Call In Link. Upon completion of the registration link, call-in participants will receive the dial-in info and a unique PIN to join the call as well as an email confirmation with the details. Replay: A webcast replay will be available in the Investor Relations section of the Company's website at or About NeurAxis, Inc., is a medical technology company focused on neuromodulation therapies to address chronic and debilitating conditions in children and adults. NeurAxis is dedicated to advancing science and leveraging evidence-based medicine to drive adoption of its IB-Stim™ therapy, which is its proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology, by the medical, scientific, and patient communities. IB-Stim™ is FDA cleared for functional abdominal pain associated with irritable bowel syndrome (IBS) in adolescents 8-21 years old. Additional clinical trials of PENFS in multiple pediatric and adult conditions with large unmet healthcare needs are underway. For more information, please visit Forward-Looking Statements Certain statements in this press release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical fact are forward-looking statements. Forward-looking statements are based on management's current assumptions and expectations of future events and trends, which affect or may affect the Company's business, strategy, operations or financial performance, and actual results and other events may differ materially from those expressed or implied in such statements due to numerous risks and uncertainties. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. There are a number of important factors that could cause actual results, developments, business decisions or other events to differ materially from those contemplated by the forward-looking statements in this press release. These factors include, among other things, the conditions in the U.S. and global economy, the trading price and volatility of the Company's stock, public health issues or other events, the Company's compliance with applicable laws, the results of the Company's clinical trials and perceptions thereof, the results of submissions to the FDA, and factors described in the Risk Factors section of NeurAxis's public filings with the Securities and Exchange Commission (SEC). Because forward-looking statements are inherently subject to risks and uncertainties, you should not rely on these forward-looking statements as predictions of future events. These forward-looking statements speak only as of the date of this press release and, except to the extent required by applicable law, the Company undertakes no obligation to update or revise these statements, whether as a result of any new information, future events and developments or otherwise. Contacts: CompanyNeurAxis, Investor RelationsBen ShamsianLytham Partners646-829-9701shamsian@
Yahoo
04-08-2025
- Business
- Yahoo
Box Sets Date to Announce Second Quarter Fiscal 2026 Financial Results
REDWOOD CITY, Calif., August 04, 2025--(BUSINESS WIRE)--Box, Inc. (NYSE:BOX) today announced that it will report financial results for its second quarter fiscal 2026, which ended July 31, 2025, following the close of the market on Tuesday, August 26, 2025. On that day, Box's management will hold a conference call and webcast at 2:00 p.m. PT to discuss Box's financial results and business developments. The conference call can be accessed by registering online at at which time registrants will receive dial-in information as well as a conference ID. What: Box Second Quarter Fiscal 2026 Earnings Conference Call When: Tuesday, August 26, 2025 Time: 2:00 p.m. PT Webcast: A live webcast will be accessible from the Box investor relations website at A replay will be available at the same webcast link until 11:59 p.m. ET on September 2, 2025. About Box Box (NYSE:BOX) is the leader in Intelligent Content Management. Our platform enables organizations to fuel collaboration, manage the entire content lifecycle, secure critical content, and transform business workflows with enterprise AI. Founded in 2005, Box simplifies work for leading global organizations, including AstraZeneca, JLL, Morgan Stanley, and Nationwide. Box is headquartered in Redwood City, CA, with offices across the United States, Europe, and Asia. Visit to learn more. And visit to learn more about how Box empowers nonprofits to fulfill their missions. Safe Harbor for Forward-Looking Statements During the course of this event, Box will make forward-looking statements regarding future events or the future financial performance of the company. Statements including words such as "anticipate," "believe," "estimate," or "expect" and statements in the future tense are forward-looking statements. These forward-looking statements are subject to risks and uncertainties that could cause actual events or actual future results to differ materially from those set forth in the forward-looking statements. Please refer to Box's latest Quarterly Report on Form 10-Q for the fiscal quarter ended April 30, 2025 for a discussion of important factors that could cause actual events or actual results to differ materially from those discussed during this event. These forward-looking statements speak only as of the date of the event; Box assumes no obligation, and does not necessarily intend, to update these forward-looking statements. View source version on Contacts Investor Relations:Cynthia Hiponia / Elaine Gaudioso650-209-3463ir@ orMedia Contact:Sheridan Hooverpress@
